Niamh M O'connell

List of Publications by Year
in descending order

38 papers	1,689 citations	516561 16 h-index	360920 35 g-index
38 all docs	38 docs citations	38 times ranked	2141 citing authors

#	Article	IF	Citations
1	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. Blood Advances, 2023, 7, 302-308.	2.5	3
2	Total Knee Arthroplasty in Hemophilia: Survivorship and Outcomesâ€"A Systematic Review and Meta-Analysis. Journal of Arthroplasty, 2022, 37, 581-592.e1.	1.5	13
3	Changing paradigms of hemophilia care across larger specialized treatment centers in the European region. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	1.1	1
4	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. Journal of Thrombosis and Haemostasis, 2021, 19, 701-710.	1.9	7
5	Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia, 2021, 27, 221-228.	1.0	10
6	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia, 2021, 27, 544-562.	1.0	12
7	Prolonged elevation of Dâ€dimer levels in convalescent COVIDâ€19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	1.9	142
8	Realâ€world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal followâ€up in a national adult cohort. Haemophilia, 2021, 27, 618-625.	1.0	9
9	Recombinant factor IXâ€Fc fusion protein in severe hemophilia B: Patientâ€reported outcomes and healthâ€related quality of life. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12602.	1.0	4
10	Single centre, realâ€world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. Haemophilia, 2021, 27, e690-e697.	1.0	7
11	Bleeding Outcomes in People with Von Willebrand Disease Receiving Antithrombotic Therapy. Blood, 2021, 138, 3196-3196.	0.6	1
12	Telehealth for delivery of haemophilia comprehensive care during the COVIDâ€19 pandemic. Haemophilia, 2020, 26, 984-990.	1.0	31
13	More on COVIDâ€19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	1.2	73
14	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	1.2	307
15	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. Blood, 2020, 136, LBA-6-LBA-6.	0.6	11
16	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
17	Missed at first Glanz: Glanzmann thrombasthenia initially misdiagnosed as Von Willebrand Disease. Transfusion and Apheresis Science, 2019, 58, 58-60.	0.5	5
18	Management of combined factor V and factor VIII deficiency in pregnancy. Journal of Obstetrics and Gynaecology, 2019, 39, 271-272.	0.4	4

#	Article	IF	Citations
19	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	2.5	79
20	The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. Transfusion and Apheresis Science, 2018, 57, 502-506.	0.5	7
21	The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL). Blood, 2018, 132, 1178-1178.	0.6	0
22	The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics. Blood, 2018, 132, 1190-1190.	0.6	0
23	The patientsâ€™ perspective of international normalized ratio selfâ€testing, remote communication of test results and confidence to move to selfâ€management. Journal of Clinical Nursing, 2017, 26, 4379-4389.	1.4	6
24	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	0.6	98
25	Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters. Thrombosis, 2016, 2016, 1-3.	1.4	5
26	Novel Insights into the Clinical Phenotype and Pathophysiology Underlying Low VWF Levels: The Low Von Willebrand Factor in Ireland Cohort (LoVIC) Study. Blood, 2016, 128, 873-873.	0.6	2
27	Guideline for the diagnosis and management of the rare coagulation disorders. British Journal of Haematology, 2014, 167, 304-326.	1.2	266
28	A 5-day: the favourable way?. Annals of Hematology, 2014, 93, 1619-1620.	0.8	1
29	A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy. Leukemia and Lymphoma, 2014, 55, 2950-2951.	0.6	1
30	Allogeneic Hematopoietic Stem Cell Transplantation for aBCR-FGFR1Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia. Case Reports in Hematology, 2012, 2012, 1-5.	0.3	17
31	Clinical conditions and patient factors significantly influence diagnostic utility of D-dimer in venous thromboembolism. Blood Coagulation and Fibrinolysis, 2009, 20, 244-247.	0.5	7
32	Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Human Mutation, 2005, 26, 192-198.	1.1	59
33	Factor XI deficiency. Seminars in Hematology, 2004, 41, 76-81.	1.8	80
34	Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion, 2003, 43, 1711-1716.	0.8	120
35	Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagulation and Fibrinolysis, 2003, 14, S35-S38.	0.5	50
36	Factor XI deficiency - from molecular genetics to clinical management. Blood Coagulation and Fibrinolysis, 2003, 14, S59-S64.	0.5	58

#	Article	IF	Citations
37	Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood, 2003, 101, 4783-4788.	0.6	122
38	Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. British Journal of Haematology, 2002, 116, 632-635.	1.2	39